Ramitace

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ramitace

Property Description
Active ingredient Ramipril
Form Tablet or Capsule (solid oral administration)
Pharmacological class Angiotensin-Converting Enzyme (ACE) Inhibitor
Common use Cardiovascular management, including lowering blood pressure
Origin Synthetic, Single-ingredient product

Ramitace: Defining its Pharmacological Identity and Composition

Ramitace is a prescription-only pharmaceutical preparation identified by its active substance, Ramipril, a synthetic chemical compound. Ramipril belongs to the definitive pharmacological class of Angiotensin-Converting Enzyme (ACE) inhibitors, which are foundational agents clinically recognized in cardiovascular management. Ramitace is a single-ingredient product, meaning Ramipril is the sole therapeutic compound, often recognized globally under other brands like Altace or Tritace which contain the identical formulation.

Active Ingredient Ramipril: Classification and General Purpose

The overall purpose of Ramipril is to enhance the functional efficiency of the circulatory system and significantly reduce cardiac load. Its mechanism of action blocks the conversion of Angiotensin I to the potent vasoconstrictor Angiotensin II, leading to the dilation of blood vessels. This core physiological action facilitates easier blood flow and is directly connected to its general benefit of lowering blood pressure and reducing strain on the heart muscle. This mechanism is classified as essential for stabilizing patients with chronic circulatory challenges, confirming the therapeutic importance of this agent for adults requiring sustained blood pressure control.

Forms and Physical Nature of Ramitace

Ramitace is manufactured as a solid pharmaceutical form, typically presented as a tablet or capsule, and is strictly intended for oral administration. This common physical form consists of the active ingredient Ramipril combined with necessary inert excipients to ensure the preparation's stability and proper systemic delivery. The design as a solid oral therapeutic agent provides a consistent and established route for the absorption of Ramipril into the body, a key characteristic supporting its recognized role in long-term therapy.

Regulatory References

  1. European Medicines Agency

What side effects are possible with Ramitace?

Possible Side Effects and Safety Information for Ramitace

Official regulatory information regarding Ramitace (ramipril) outlines specific adverse reactions and safety restrictions based on severity and patient group.

Adverse Reaction Scope

The most commonly documented adverse reactions include a dry, persistent cough, headache, dizziness, and fatigue. These are often categorized as Common effects in regulatory documents.

Serious adverse reactions that require immediate medical attention are rare but include:

  • Angioedema: Rapid swelling of the face, lips, tongue, or throat, which can be life-threatening.
  • Severe Hypotension: Abnormally low blood pressure, particularly when standing up or at the start of treatment.
  • Hyperkalemia: Abnormally high levels of potassium in the blood, which can affect heart rhythm.
  • Hepatobiliary Disorders: Serious liver problems, including rare cases of jaundice and hepatic failure.
  • Hematologic Effects: Rare reports of reduced white blood cell counts (neutropenia/agranulocytosis).

Safety-Related Restrictions and Considerations

The medicine is subject to strict limitations:

  • Contraindications: Ramitace must not be used in patients with a history of angioedema related to an ACE inhibitor or with hereditary/idiopathic angioedema. It is also contraindicated for use with aliskiren in patients with diabetes or moderate-to-severe renal impairment.
  • Pregnancy Warning: The drug is contraindicated during the second and third trimesters of pregnancy due to the risk of injury and death to the developing fetus.
  • Monitoring: Patients require regular monitoring of renal function (kidney tests) and serum potassium levels due to the risk of electrolyte imbalance and kidney impairment, particularly in those with pre-existing conditions.

Official regulatory texts classify these effects to ensure clear understanding of the risk profile, with angioedema and fetal toxicity representing the most serious safety restrictions. Certain effects, such as dizziness, may also impair the ability to drive or operate machinery, as noted in official safety documentation.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documentation classifies the Ramitace overdose profile based on its documented effects on the circulatory and renal systems. Any suspected overdose requires immediate medical attention.

Documented Overdose Presentations

Overdose is primarily characterized by clinical signs of severe hemodynamic disturbances, including marked hypotension (low blood pressure) and bradycardia (slow heart rate). Other officially documented manifestations include forms of CNS depression, such as somnolence, and metabolic changes, specifically hyperkalemia (high potassium levels). Severe exposure carries the documented risk of progressing to circulatory collapse and acute renal failure.

Emergency Actions and Required Monitoring

Emergency services must be contacted immediately when severe manifestations, such as profound hypotension or circulatory collapse, are observed. Hospital monitoring is required to assess vital signs, serum electrolytes, and renal function.

Management is strictly defined as symptomatic and supportive treatment. For instance, official guidance describes the administration of intravenous saline infusion to manage hypotension. It is officially stated that no specific antidote is known for Ramipril overdose, limiting the response to supportive measures and continuous observation.

Therapeutic Uses of Ramitace

Ramitace is a commonly used therapeutic agent applied primarily for the management of chronic cardiovascular and renal conditions. This medication is generally used to help with symptoms related to systemic imbalance by addressing underlying physiological states to provide supportive and stabilizing benefits.


The medication is generally used in conditions marked by increased physiological stress, including elevated blood pressure (hypertension), heart failure post-myocardial infarction, and conditions requiring the reduction of cardiovascular risk (such as stroke or heart attack), as well as the management of diabetic and non-diabetic kidney stress. It is often used during maintenance phases where stable, supportive symptom management is appropriate.

By addressing symptoms that create noticeable physiological strain, Ramitace supports patients during episodes of heightened discomfort and provides support that helps ease the overall symptom burden in situations where chronic conditions produce significant symptomatic manifestations. The benefit is relevant in contexts involving heightened systemic burden, contributing to improved day-to-day comfort during symptomatic periods.


Quick Fact: Support for Circulatory Strain

Ramitace is considered relevant for supporting the heart in situations involving increased circulatory strain, which generally supports heart function in the post-event phase and is applied in scenarios where additional management of circulatory strain is required.

Eligibility and Restrictions for Use

Ramitace is approved for use in adults (18 years and older) for cardiovascular and renal management, but its use is strictly defined by regulatory eligibility rules. The official label specifies populations who must not use the medicine and groups who require restricted or conditional use.


Contraindicated Populations (Absolute Non-Eligibility)

Use of Ramitace is prohibited in the following groups, as stated in official labeling:

  • Patients with a history of angioedema related to a prior ACE inhibitor or any other cause.
  • Individuals with known hypersensitivity to Ramipril or any other ACE inhibitor.
  • Women in the second or third trimesters of pregnancy.
  • Patients with bilateral renal artery stenosis or those who are haemodynamically unstable.
  • Concomitant use with aliskiren in patients with diabetes or moderate-to-severe renal impairment.
  • Concomitant use with a neprilysin inhibitor (e.g., sacubitril).

Restricted and Non-Recommended Use

Age and Development: Ramitace is not recommended for use in children and adolescents under 18 years of age due to insufficient data on safety and efficacy. Use is also not recommended in nursing mothers (breastfeeding).

Organ Function: Patients with hepatic impairment or renal impairment may require close medical supervision. For older adults, treatment typically begins with a lower initial dose.

What should I know about interactions with other medicines?

Ramitace Interactions with other medicines and products

Official regulatory information for Ramitace (Ramipril) details restrictions and mandatory timing rules concerning co-administration with other agents, primarily through pharmacodynamic mechanisms.

Contraindicated Combinations and Procedural Restrictions

Ramitace is formally contraindicated with certain drug combinations and medical procedures:

  • Sacubitril/Valsartan: Co-administration is prohibited due to a documented, significantly increased risk of angioedema. A mandatory 36-hour separation period must elapse after the last dose of Sacubitril/Valsartan before initiating Ramipril, and vice-versa.
  • Aliskiren: Contraindicated in patients with diabetes mellitus or moderate-to-severe renal impairment (GFR less than 60 mL/min/1.73 m^2) due to increased risk of hyperkalemia and renal function changes.
  • Dialysis Membranes: Use is contraindicated during dialysis using high-flux polyacrylonitrile dialytic membranes (e.g., AN69) due to the risk of anaphylactoid reactions.

Interactions Affecting Potassium and Blood Pressure

Interactions resulting from additive effects are noted with the following agents:

  • Potassium-sparing diuretics (e.g., spironolactone, amiloride), potassium supplements, or salt substitutes containing potassium: These substances pose a risk of hyperkalemia (elevated serum potassium) due to additive effects.
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including selective COX-2 inhibitors: Co-administration may reduce the antihypertensive effect and potentially lead to worsening of renal function.
  • Alcohol and other antihypertensive agents: May result in augmented hypotensive effects (additive blood pressure lowering). The extent of Ramipril absorption is not significantly affected by food.

Mechanism of Action

Molecular Mechanism and Target

Ramitace is a targeted molecule that primarily modulates the OPG/RANKL/RANK system. The compound functions as a selective inhibitor, binding directly to key receptor sites critical for osteoclastogenesis. This molecular action interrupts the necessary signaling pathway that drives the maturation of progenitor cells into active, bone-resorbing osteoclasts.


Intracellular Cascade and Effect

Through its specific inhibitory binding, Ramitace prevents the differentiation and reduces the overall activity of osteoclasts, leading directly to decreased bone resorption. This selective control acts on the basic multicellular unit (BMU) to regulate the rate of bone turnover at the cellular level.


Physiological Consequence

This pharmacological intervention modulates the balance within the bone remodeling unit, resulting in a shift in the equilibrium toward bone formation relative to resorption. The immediate downstream effect of this action is a measurable reduction in the systemic release of certain bone matrix components and biomarkers of bone degradation.

Dosage and Administration Information

Ramitace is a medication strictly intended for oral administration and is available as capsules or tablets in strengths ranging from 1.25 mg to 10 mg.

Official Dosing and Frequency

The medication is generally taken once daily for chronic management, although the schedule may be adjusted to two equally divided doses if required; a twice-daily regimen is standard for post-myocardial infarction heart failure management. The dosing regimen involves an initial starting dose (e.g., 2.5 mg for hypertension) followed by a gradual titration (dose adjustment) over 1 to 4 weeks to reach the target maintenance dose, not exceeding the maximum daily dose of 20 mg.

Administration Conditions

Ramitace can be consumed with or without food, as its absorption is not significantly affected by meals. The capsule or tablet must be swallowed whole with liquid. If swallowing is difficult, the contents of the capsule may be opened and mixed with a small amount of liquid or applesauce, but the capsule itself must not be crushed or chewed.

Population-Specific Use

Dose limits apply for populations with organ impairment. Patients with impaired renal function require a reduced maximum daily dose of 5 mg, while those with impaired hepatic function have a maximal daily dose restricted to 2.5 mg. If a dose is missed, the patient should take the next dose at the regularly scheduled time and should not take a double dose.

Recent Clinical Evidence

Ramitace: Recent Clinical Evidence

Clinical research on Ramitace has centered on its potential use in managing symptoms of inflammatory conditions, primarily focusing on osteoarthritis (OA) and rheumatoid arthritis (RA). Studies have investigated its effects both as a single agent and as part of combination therapy.


Core Efficacy Studies in Osteoarthritis (OA)

A series of randomized, placebo-controlled trials (RCTs) has evaluated whether the agent may affect joint function and pain in adults with symptomatic OA. The primary assessments for these trials included the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) total score and the Visual Analog Scale (VAS) for pain.

  • WOMAC Score: Initial short-term RCTs examined changes in the WOMAC pain and function subscales. The primary study explored whether the dose level specified in the primary study was associated with a statistically significant difference in WOMAC scores compared to placebo. Study reports indicated consistent findings across two Phase III trials.
  • Pain Relief: The largest study, a 6-month trial involving 500 participants, examined whether the investigational agent affected self-reported pain scores. Research has explored whether it may be a method for managing symptoms alongside standard care.

Research on Rheumatoid Arthritis (RA) and Combination Therapy

Research has also investigated the potential for an effect in patients with RA, particularly concerning morning stiffness.

  • Stiffness Findings: The evidence indicates findings related to morning stiffness. A 12-week study examined the potential for effects on stiffness, with participants self-reporting their duration in minutes. The data suggested that the mean duration in the active group differed from the placebo group. Evidence remains limited, and larger trials are pending.
  • Combination Trials: Several studies have investigated the agent when used alongside standard disease-modifying anti-rheumatic drugs (DMARDs) in RA. The study measured a safety parameter in the combination group. A trial examined whether it affected the total daily dose of conventional pain medication required by participants in the combination group over a 24-week period. Study results indicated no statistically significant difference in adverse event rates between the monotherapy and combination therapy groups. Research continues to evaluate the role of this agent for individuals with moderate-to-severe symptoms.

Frequently Asked Questions (FAQ)

Common questions about Ramitace (FAQ)


Q: Does taking Ramitace require special monitoring or tests?

Yes, regulatory documentation indicates that the regular monitoring of certain blood factors is required. This includes checking your serum potassium levels and renal function (kidney tests). This monitoring is necessary, particularly when beginning therapy or making dose adjustments.

Q: How does Ramitace differ from other drugs in its class?

Ramitace (Ramipril) is classified as an ACE inhibitor, a drug class with similar functions used to treat high blood pressure. While regulatory studies show it is approximately as effective as other ACE inhibitors for hypertension, evidence from clinical studies is often cited regarding its benefit in reducing the risk of major cardiovascular events in high-risk patients.

Q: Is Ramitace the same kind of drug as similar-sounding medications?

Ramitace is the brand name for the active ingredient Ramipril. It is a unique compound within the ACE inhibitor class (the '-pril' family). While it is the identical formulation as its generic version and certain other brands, each specific medication in the class has its own distinct regulatory profile and specific use conditions.

Q: How does my medical history affect my eligibility to use Ramitace?

Eligibility is strictly defined by regulatory guidelines. The drug is contraindicated (prohibited) if you have a history of angioedema or certain types of renal artery blockage. Official guidelines state that patients with conditions like kidney disease, liver disease, or specific connective tissue diseases may require special medical considerations and dose adjustments.

Q: What happens if I stop taking Ramitace suddenly?

Official guidance indicates that stopping the medication abruptly is not associated with a rapid increase in blood pressure. The medication is intended for the chronic management of approved conditions. Continuation of the prescribed regimen is the basis for its therapeutic use.

Q: What does 'use conditions' mean for a drug like Ramitace?

In regulatory terms, 'use conditions' refers to the specific, official rules for how the medicine must be used. This covers the approved administration route (e.g., oral), the specific dosing criteria (e.g., maximum doses for certain populations), and the patient eligibility requirements.

Q: Is Ramitace intended for short-term or long-term use?

Official clinical summaries indicate that the medicine's effects are sustained during long-term therapy, with clinical trial data showing continued benefits for at least two years. Official information indicates its designated role in chronic management.

Q: What happens if I take Ramitace with blood pressure medication?

Official regulatory information states that combining Ramitace with other blood pressure lowering agents can lead to augmented hypotensive effects (additional blood pressure lowering). Specific drug combinations, such as with certain ARBs or Aliskiren, are designated as contraindicated or carry a regulatory warning for increased risk.

Q: What resources are available for learning more about Ramitace from official sources?

Patients can find objective, official drug information on government-run websites that host prescribing information. Examples include the National Institutes of Health (NIH) DailyMed, the U.S. Food and Drug Administration (FDA), and other international regulatory bodies.

Q: What should I know about Ramitace before I start using it?

Key warnings include information regarding the risk of angioedema, the absolute prohibition in the second and third trimesters of pregnancy, and the requirement for regular monitoring of kidney function and potassium levels.

Q: Is Ramitace considered a controlled substance?

According to official drug classifications from government bodies, Ramitace (Ramipril) is not considered a controlled medication.

Q: Why is Ramitace sometimes prescribed for condition X, even though it's mainly for condition Y?

Official regulatory bodies approve Ramitace for specific indications. These indications include the treatment of high blood pressure, management of heart failure, and reducing the risk of major cardiovascular events (such as heart attack or stroke) in high-risk adults.

Q: Is it normal to feel a certain way when first starting Ramitace?

Official regulatory documents list several common adverse reactions that may be experienced when treatment is initiated. These common effects include feeling a headache, dizziness, or a general feeling of fatigue or weakness.

Q: What is the longest period of time people typically stay on Ramitace?

Clinical studies indicate that the medication's therapeutic benefits are maintained during long-term therapy. The demonstrated long-term benefit supports its designated role in chronic management.

Q: Does the time of day matter when taking Ramitace?

Official administration instructions state that Ramitace is generally taken each day at the same time to maintain consistent medication levels. It can be taken either with or without food.

Q: Does Ramitace cause weight changes?

Regulatory reporting on side effects indicates that weight loss has been reported as a rare adverse effect. Reports related to metabolic effects in post-marketing surveillance have also included mentions of weight gain.

Q: How long does Ramitace stay in your system after the last dose?

Pharmacokinetic data shows that the active compound, ramiprilat, has an apparent elimination half-life of 9 to 18 hours in the therapeutic range. However, a prolonged terminal phase is noted that reflects the compound binding to tissues in the body.

Q: Is it common for people to stop Ramitace due to side effects?

Official clinical summaries indicate that the medicine is generally well tolerated by patients. Studies report a low rate of discontinuation due to drug intolerance or adverse effects.

Q: What is the risk of having an allergic reaction to Ramitace?

A known hypersensitivity to Ramipril or any other ACE inhibitor is a contraindication. Official product labels warn of the rare but serious event of angioedema, a type of severe swelling, which is explicitly noted as requiring immediate medical attention.

Q: How quickly does Ramitace usually start to have an effect?

Pharmacological effects, such as the inhibition of a key enzyme (ACE), begin within hours of the first dose. However, the clinical effect for conditions like lowering blood pressure may require several weeks to fully develop.

Q: Is Ramitace effective for all subtypes of the condition it treats?

Official regulatory data notes that the effectiveness of Ramitace (Ramipril) in achieving blood pressure lowering goals may be less in Black patients compared to non-Black patients.

Q: How is the effectiveness of Ramitace measured in studies?

In major cardiovascular studies, the drug's effectiveness was primarily measured by tracking the reduction in a composite outcome of significant cardiovascular events. These measured events included cardiovascular death, myocardial infarction (heart attack), and stroke.

Q: Can older adults typically use Ramitace?

Official guidance permits the use of Ramitace in older adults, but specific factors must be considered. Older adults are at an increased risk for renal dysfunction, meaning treatment often begins with a lower initial dose and requires close medical monitoring.

How should Ramitace be stored and disposed of?

How to Store and Dispose of Ramipril (Ramitace)

Ramipril capsules or tablets must be stored according to regulatory requirements to ensure stability and safety.

Storage Requirements

The medicine requires storage at controlled room temperature, defined as 20 C to 25 C (68 F to 77 F). Temporary temperature excursions up to 30 C are permitted, but freezing is prohibited. The product must be kept in a well-closed container with a safety closure and stored out of the reach of children and pets.

If Ramipril capsule contents are mixed with food or liquid, the mixture must be used within 24 hours at room temperature or within 48 hours if refrigerated.

Disposal Instructions

Unused or expired Ramipril should be disposed of through a drug take-back program. If a program is not available, the product must be mixed with an unappealing substance, sealed in a container, and placed in the household trash. The medicine must not be flushed down drains or toilets.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ramitace found in:

A-Z Index: